Appointment sheet
Chondrosarcoma
Prepared with OnCo (onco.cc/prep/chondrosarcoma/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
17 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example IDH1 or IDH2 mutation, Histological grade 1 to 3 and dedifferentiation, HEY1-NCOA2 fusion, COL2A1 mutations, Site), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Atypical cartilaginous tumour of the limbs
- 5.For my situation (atypical cartilaginous tumour of the limbs), which of the standard options do you recommend and why?
Conventional grade 2 to 3, resectable
- 6.For my situation (conventional grade 2 to 3, resectable), which of the standard options do you recommend and why?
Skull base and spine, incompletely resectable
- 7.For my situation (skull base and spine, incompletely resectable), which of the standard options do you recommend and why?
Dedifferentiated and mesenchymal
- 8.For my situation (dedifferentiated and mesenchymal), which of the standard options do you recommend and why?
- 9.Am I a candidate for Doxorubicin, Cisplatin, Ifosfamide, and what side effects should I expect?
Advanced IDH1-mutant conventional
- 10.For my situation (advanced idh1-mutant conventional), which of the standard options do you recommend and why?
- 11.Am I a candidate for Ivosidenib, and what side effects should I expect?
- 12.How do the results of Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen apply to someone like me?
Any stage
- 13.Are there clinical trials I could join, for example of Ivosidenib, Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen, IDH inhibitors, Carbon-ion therapy?
- 14.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 15.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 16.I read that “No systemic therapy has ever been proven to help”. How does that affect my plan?
- 17.I read that “Dedifferentiated chondrosarcoma kills most patients within two years”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: IDH1 or IDH2 mutation (ivosidenib eligibility), Histological grade 1 to 3 and dedifferentiation, HEY1-NCOA2 fusion (mesenchymal), COL2A1 mutations, Site (limb versus pelvis and axial skeleton).
Scans and tests linked to this cancer: Active surveillance, MRI.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Conventional grade 2 to 3, resectable: Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins. (Limb-salvage surgery and endoprosthetic reconstruction, IMRT / IGRT (modern external beam))
- Skull base and spine, incompletely resectable: Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy. (Proton therapy, Carbon-ion therapy, IMRT / IGRT (modern external beam))
- Atypical cartilaginous tumour of the limbs: Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy. (Limb-salvage surgery and endoprosthetic reconstruction, Active surveillance, MRI)
- Dedifferentiated and mesenchymal: Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain. (Doxorubicin, Cisplatin, Ifosfamide)
- Advanced IDH1-mutant conventional: Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy. (Ivosidenib, Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen, IDH inhibitors)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call